A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Stopped Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.

Conditions

• Cancer
• Tumors
• Neoplasm
• Malignancy

Interventions

• DRUG: BMS-986226
• BIOLOGICAL: Nivolumab
• BIOLOGICAL: Ipilimumab
• BIOLOGICAL: Tetanus Vaccine

Sponsor

Bristol-Myers Squibb